Stocktoria
Alkermes plc. ALKS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-07-16
Alkermes plc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% |
| Net margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% |
| FCF margin | 32.5% | 26.0% | 21.2% | -1.5% | 6.3% |
| Return on assets | 9.7% | 17.9% | 16.7% | -8.1% | -2.4% |
| Return on equity | 13.3% | 25.1% | 29.6% | -15.2% | -4.3% |
| Debt / equity | 0.00× | — | 0.24× | 0.28× | 0.26× |
| Current ratio | 3.55 | 3.04 | 2.86 | 2.27 | 2.25 |
| Revenue growth | -5.2% | -6.4% | 49.6% | -5.3% | 13.0% |
Source: SEC EDGAR filings · CIK 0001520262 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.